Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APG 157

Next Previous
Drug Profile

APG 157

Alternative Names: APG-157

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aveta Biomics
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Oropharyngeal dysplasia; Squamous cell cancer
  • Phase I/II Glioblastoma
  • Phase I Head and neck cancer

Most Recent Events

  • 19 Dec 2024 Phase-I clinical trials in Head and neck cancer (Recurrent, Metastatic disease, Combination therapy) (PO) (Aveta Biomics pipeline, December 2024)
  • 13 Dec 2023 Phase-I/II clinical trials in Glioblastoma in USA (Combination therapy, Late-stage disease, Recurrent) (PO) (NCT06011109)
  • 30 Aug 2023 Aveta Biomics plans a phase I/II trial for Glioblastoma (Late stage disease, Combination therapy, Recurrent) in USA (PO, pastilles) in September 2023 (NCT06011109)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top